

> Classification (Circ 2014;130:e199)


# ATRIAL FIBRILLATION

### Classification (_Circ_ 2014;130:e199)

• **Paroxysmal** (self-terminating, usually <48 h, often triggered in pulm veins) vs. **persistent** (>7 d) vs. **long-standing persistent** (>1 y) vs. **permanent** (no plan for SR)

• **Nonvalvular** (AF absent rheumatic MS, prosthetic valve, or mitral valve repair) vs. **valvular**

### 流行病學 and 原因 (_Circ_ 2011;124:1982; _Nat Rev_ 2016;2:1)

• 1–2% of pop. has AF (10% of those age ≥80); M > F; lifetime risk ~25%

• Acute (up to 50% without identifiable cause)

**Cardiac:** HF, new CMP, myo/pericarditis, ischemia/MI, HTN crisis, valve dis., cardiac surg

**Pulmonary:** acute pulmonary disease or hypoxemia (eg, COPD flare, PNA), PE, OSA

**Metabolic:** high catecholamine states (stress, infection, postop, pheo), thyrotoxicosis

**Drugs:** alcohol, cocaine, amphetamines, theophylline, caffeine, smoking, ibrutinib

**Neurogenic:** subarachnoid hemorrhage, ischemic stroke

• Chronic: ↑ age, HTN, ischemia, valve dis. (MV, TV, AoV), CMP, hyperthyroidism, obesity

### Evaluation

• H&P, ECG, CXR, TTE (LA size, thrombus, valves, LV fxn, pericardium), K, Mg, Cr, FOBT before anticoag, TFTs; 排除 MI not necessary unless other ischemic sx

• In acute AF <48º, ~70% spont. convert to SR within 48 hrs (_NEJM_ 2019;380:1499)

### Figure 1-5 Approach to acute AF (Adapted from _Circ_ 2014;130:e199)

![](https://i.imgur.com/ZEwKrgv.jpg)

![](https://i.imgur.com/EAXJjJ8.jpg)

_Lancet_ 2016;388:818. IV βB, CCB & dig **_contraindic._** if evidence (ie, pre-excitation or WCT) of WPW (qv).

\*Many meds incl. amio, verapamil, quinidine, propafenone, macrolides & azole antifungals ↑ digoxin levels.

### Cardioversion

• Consider if: 1st AF, sx, tachycardia-mediated CMP, or difficult to rate control

If AF >48 h 2–5% risk stroke with cardioversion (_pharmacologic or electric_) ∴ either TEE to 排除 thrombus or ensure therapeutic anticoagulation ≥3 wk prior

If needs to cardiovert urgently, often anticoagulate acutely (eg, IV UFH)

• Likelihood of success ∝ AF duration & atrial size; control precipitants (eg, vol status, thyroid)

• Before electrical cardiovert, consider pre-Rx with AAD (eg, ibutilide), esp. if 1st cardiovert failed

• For pharmacologic cardioversion, class III and IC drugs have best proven efficacy

• If SR returns (spont. or with Rx), atria may be _mech. stunned;_ also, high risk of recurrent AF over next 3 mo. ∴ **Anticoag postcardioversion** ≥**4 wk** (? unless AF <48 h and low risk).

### Rhythm control (_Lancet_ 2016;388:829)

• No ↓ mortality or stroke vs rate control (_NEJM_ 2002;347:1825 & 2008;358:2667 & 2016;374:1911)

• Consider if _sx_ with rate control (eg, HF), difficult to control rate, or tachycardia-mediated CMP

![](https://i.imgur.com/vQwByfJ.jpg)

### Ablation

• Pulm vein isolation (radiofreq or cryo; _NEJM_ 2016;374:2235): ~70% success; no need to interrupt anticoag; superior to AAD (_JAMA_ 2014;311:692) & ↑ 生活品質 (_JAMA_ 2019;321:1059)

• If NYHA II-IV + EF <35%, ablation ↓ D/HF hosp vs. rate/rhythm meds (_NEJM_ 2018;378:417)

• AV node ablation + PPM if other Rx inadequate (_NEJM_ 2001;344:1043 & 2002;346:2062)

### Oral anticoagulation (_Circ_ 2014;130:e199 & 2019;139:epub; _EHJ_ 2018;39:1330)

• _All valvular AF_ (ie, rheum MS, valve prosthesis or repair), because stroke risk very high

• Nonvalvular AF (NVAF): stroke risk ~4.5%/y

• **CHA2DS2**\-**VASc** to guide Rx: **C**HF (1 point); **H**TN (1); **A**ge ≥75 y (2); **D**M (1), **S**troke/TIA (2); **V**ascular disease (eg, MI, PAD, Ao plaque) (1); **A**ge 65–74 (1); ♀ **S**ex **c**ategory (1)

Annual risk of stroke (_Lancet_ 2012;379:648): at low end, ~1% per point: 0 → ~0%, 1 → 1.3%, 2 → 2.2%, 3 → 3.2%, 4 → 4.0%; at higher scores, risk ↑↑ (5 → 6.7%, ≥6 → ≥10%)

### Score ≥**2** → **anticoagulate; score 1** → **consider anticoag.** or ASA (? latter reasonable if risk factor 65–74 y, vasc dz or ♀) or no Rx; **score 0** → reasonable to not Rx

• **Rx options: DOAC** (NVAF only) prefered over warfarin (INR 2–3); if Pt refuses anticoag, ASA + clopi or, even less effective, ASA alone (_NEJM_ 2009;360:2066)

• AF + CAD/ PCI: consider DOAC (some data for reduced dose but unclear if ischemic stroke prevention adequate), clopi (not ticag or prasugrel), and consider stopping ASA (? after ~1 wk) (_Lancet_ 2013;381:1107; _NEJM_ 2016;375:2423 & 2017;377:1513 & 2019;380:1509).

• If concern for procedural bleed, interrupt OAC (1–2 d DOAC, 4–5 d VKA). If CHA2DS2\-VASc ≥7 (or ≥5 with h/o CVA/TIA), consider bridge with UFH/LMWH, else no (_JACC_ 2017;69:735).

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Direct Oral Anticoagulants (DOACs) for NVAF</b> (<span><i>Lancet</i> 2014;383:955</span>)</p></td></tr><tr><td><p><b>Anticoag</b></p></td><td><p><b>Dosing</b></p></td><td><p><b>Efficacy &amp; Safety vs. Warfarin</b></p></td></tr><tr><td><p><b>Dabigatran</b></p><p>(Direct thromb inhib)</p></td><td><p>150 mg bid (110 not avail in U.S.) (75 mg bid if CrCl 15–30)</p></td><td><p>150 mg: ↓ ischemic stroke &amp; ICH, but ↑ GIB</p><p>110 mg: ≈ ischemic stroke &amp; ↓ major bleed/ICH</p><p>Risks: GI side effects, ↑ MI c/w warfarin</p></td></tr><tr><td><p><b>Rivaroxaban</b></p><p>(FXa inhib)</p></td><td><p>20 mg qd (15 mg qd if CrCl 15–50) with pm meal</p></td><td><p>≈ ischemic stroke &amp; major bleeds, but ↓ fatal bleed incl ICH</p></td></tr><tr><td><p><b>Apixaban</b></p><p>(FXa inhib)</p></td><td><p>5 mg bid (2.5 mg bid if ≥2 of: ≥80 y, ≤60 kg, Cr ≥1.5 mg/dL)</p></td><td><p>≈ ischemic stroke &amp; ↓ major bleed incl ICH,</p><p>11% ↓ death. In 病人 felt not cand for warfarin, apixa 55% ↓ stroke without ↑ bleed vs ASA alone.</p></td></tr><tr><td><p><b>Edoxaban</b></p><p>(Fxa inhib)</p></td><td><p>60 mg qd if CrCl 51–95 (30 mg if CrCl 15–50)</p></td><td><p>≈ ischemic stroke &amp; ↓ major bleed incl ICH, 14% ↓ CV death. ↑ ischemic CVA if CrCl &gt;95.</p></td></tr><tr><td colspan="3"><p>Onset within hrs. Reversal: idarucizumab for dabi; andexanet for FXa; 4F-PCC.</p></td></tr></tbody></table>

### Nonpharmacologic stroke prevent (_JACC_ 2015;66:1497)

• If contraindic. to long-term OAC, consider perc. left atrial appendage (LAA) occlusion (_JACC_ 2017;70:2964). Nb, ideally warfarin + ASA × 45 d → DAPT out to 6 mo → ASA.

• Consider perc. epicardial LAA ligation or surgical resection if undergoing other card surg

### Atrial flutter

• Macroreentrant atrial loop. Typical involves cavotricuspid isthmus (if counterclockwise, flutter waves ⊖ in inf leads, if clockwise, ⊕). Atypical: other pathways related to prior scar.

• Risk of stroke similar to that of AF, ∴ anticoagulate same as would for AF

• Ablation of typical (cavotricuspid isthmus) AFL has 95% success rate
